TTC39B Antibody / C9orf52

Overview

TTC39B Antibody / C9orf52 is an antibody targeting TTC39B, raised in Rabbit for protein detection and localization studies where these specifications are required.

Key elements and design rationale

• Target: TTC39B.
• Antibody identity: Polyclonal (rabbit origin); Rabbit IgG.
• Conjugate/label: Unconjugated (affects detection chemistry and multiplex compatibility).
• Format: Antigen affinity purified.
• Species reactivity: Human, Mouse, Rat.
• Listed applications: WB, FACS, Direct ELISA (refer to on-page specifications for application-specific guidance).

Biological background

Tetratricopeptide repeat protein 39B is a protein that in humans is encoded by the TTC39B gene. TTC39B protein contains two TPR repeats (aa 39 3-426 and 626 -659). TCC39B protein is the product of a high density lipoprotein (HDL) gene that promotes the ubiquitination and degradation of liver X receptor (LXR). TTC39B null or deficient mice challenged with high fat/cholesterol/bile salt diet exhibit increased LX R protein and target gene expression. TTC39B deficiency is reported to stabilize LXR by reducing its polyubiquitination and proteasomal degradation. Hence it reduces the incidence of atherosclerosis and steatohepatitis. TTC39B deficiency mice display higher levels of HDL and Apoplipoprotein A-1 and lower levels of hepatic triglyceride synthesis.However it does not affect glucose tolerance or hepatic gluconeogenesis.

Research relevance and current trends

• Comparative expression profiling across cell types, tissues, or perturbations (e.g., drug treatment, genetic editing, or differentiation).
• Subcellular localization and trafficking studies, including co-localization with pathway markers in microscopy-based assays.
• Integration of protein-level measurements with transcriptomics or proteomics to relate abundance to regulation and phenotype.

Common research applications

• Western blotting: researchers commonly compare relative signal levels across conditions and use appropriate negative/positive controls for interpretation.
• Flow cytometry: researchers commonly compare relative signal levels across conditions and use appropriate negative/positive controls for interpretation.
• ELISA: researchers commonly compare relative signal levels across conditions and use appropriate negative/positive controls for interpretation.

Interpretation should account for antibody-dependent factors such as epitope accessibility, isoforms, and sample preparation differences across workflows.

Notes for experimental interpretation

• Isoforms and PTMs: many targets have multiple isoforms and post-translational modifications that can shift apparent signal or localization; interpret bands/signals accordingly.
• Epitope context: binding can depend on protein conformation and sample processing; region information in the title/immunogen can help anticipate what may be detected.
• Species differences: predicted or validated reactivity may vary by ortholog sequence and sample context; confirm in your model system.
• Control concepts: include negative controls (no-primary/isotype), and where possible genetic controls (KO/KD) or independent antibodies to strengthen conclusions.

Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.